Skip to main content Accessibility help
×
Home
  • Print publication year: 2010
  • Online publication date: December 2010

Chapter 5 - Paroxysmal headaches

Related content

Powered by UNSILO

References

BrandesJL, KudrowD, StarkSR, O’CarrollCP, AdelmanJU, O’DonnellFJ, AlexanderWJ, SpruillSE, BarrettPS, LenerSE. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. Jama 2007, 297(13):1443–54.
BussoneG, DienerH, PfeilJ, SchwalenS. Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blind randomised controlled trials. Int J Clin Pract 2005, 59:961–968.
DahlöfC. Placebo-controlled clinical trials with ergotamine in the acute treatment of migraine. Cephalalgia 1993, 13:166–171.
DienerHC, RechesA, PascualJ, JansenJ-P, PiteiD, Steiner T, on behalf of the Eletriptan and Cafergot Comparative Study Group. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison. Eur Neurol 2002, 47:99–107.
DienerHC, LimmrothV. Medication-overuse headache: a worldwide problem. Lancet Neurology 2004, 3:475–483.
DienerH, PfaffenrathV, PagelerL, PeilH, AicherB. The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multi-centre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia 2005, 25:776–778.
DienerHC, LamplC, ReimnitzP, VoelkerM. Aspirin in the treatment of acute migraine attacks. Expert Rev Neurother 2006, 6(4):563–73.
DienerHC, BussoneG, Van OeneJ, LahayeM, SchwalenS, GoadsbyPJ. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2007, 27:814–823.
EdvinssonL, EkmanR, JansenI, McCullochJ, MortensenA, UddmanR. Reduced levels of calcitonin gene-related peptide-like immunoreactivity in human brain after subarachnoid haemorrhage. Neurosci Lett 1991, 121:151–154.
EdvinssonL, UddmanR. Immunohistochemical localization and dilatory effect of substance P on human cerebral vessels. Brain Res 1982, 232:466–471.
FerrariMD, RoonKI, LiptonRB, GoadsbyPJ. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001, 358:1668–1675.
GrahamJR, WolffHG. Mechanism of migraine headache and action of ergotamine tartrate. Arch Neurol Psych 1938, 39:737–763.
International Headache Society. The international classification of headache disorders. 2nd edn. Cephalalgia 2004, 24 (Suppl. 1):9–160.
KelmanL. The premonitory symptoms (prodrome): a tertiary care study of 893 migraineurs. Headache 2004, 44:865–872.
KelmanL. The triggers or precipitants of the acute migraine attack. Cephalalgia 2007, 27(5):394–402.
KlapperJ, on behalf of the Divalproex Sodium in Migraine Prophylaxis Study Group. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 1997, 17(2):103–108.
LiptonRB, StewartWF. Epidemiology and comorbidity of migraine. In: GoadsbyPJ, SilbersteinSD. (eds.). Headache. Boston: Butterworth-Heinemann, 1997, p. 75–97.
LiptonRB, BigalME, DiamondM, FreitagF, ReedML, StewartWF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007, 68(5):343–9.
LucasC, ChaffautC, ArtazMA, Lanteri-MinetM. FRAMIG 2000: medical and therapeutic management of migraine in France. Cephalalgia 2005, 25(4):267–79.
MacGregorEA, FrithA, EllisJ, AspinallL, HackshawA. Prevention of menstrual attacks of migraine: a double-blind placebo-controlled crossover study. Neurology 2006, 67(12):2159–63.
MannixLK, SavaniN, LandyS, ValadeD, ShackelfordS, AmesMH, JonesMW. Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies. Headache 2007, 47(7):1037–49.
MassiouH, BousserM-G. Influence of female hormones on migraine. In: OlesenJ, Tfelt-HansenP, WelchKMA. (eds.). The headaches. 2nd edn. Philadelphia: Lippincott, Williams & Wilkins, 2000, p. 261–267.
MathewNT, FinlaysonG, SmithTR, CadyRK, AdelmanJ, MaoL, WrightP, GreenbergSJ. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study). Headache 2007, 47(2):189–98.
McNeelyW, GoaKL. Diclofenac-potassium in migraine. Drugs 1999, 57:991–1003.
MoskowitzMA. The neurobiology of vascular head pain. Ann Neurol 1984, 16:157–168.
OlesenJ, DienerH, HusstedtIW, GoadsbyPJ, HallD, MeierU, PollentierS, LeskoLM, for the BIBN 4096 BS Clinical Proof of Concept Study Group. Calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS is effective in the treatment of migraine attacks. N Engl J Med 2004, 350:1104–1110.
Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: the utility of neuroimaging in the evaluation of headache in patients with normal neurologic examinations. Neurology 1994, 44:1353–1354.
SchoonmanGG, EversDJ, TerwindtGM, van DijkJG, FerrariMD. The prevalence of premonitory symptoms in migraine: a questionnaire study in 461 patients. Cephalalgia 2006, 26(10):1209–13.
SilbersteinSD. Migraine and women. The link between headache and hormones. Postgrad Med 1995, 97:147–153.
SilbersteinSD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000, 55:754–762.
SilbersteinSD, LiptonRB, DodickDW, FreitagFG, RamadanN, MathewN, BrandesJL, BigalM, SaperJ, AscherS, JordanDM, GreenbergSJ, HulihanJ. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 2007, 47(2):170–80.
SteinerTJ, StewartWF, KolodnerK, LibermanJ, LiptonRB. Epidemiology of migraine in the England. Cephalalgia 1999, 19:305–306.
Tfelt-HansenP, SaxenaPR, DahlöfC, PascualJ, LainezM, HenryP, DienerHC, SchoenenJ, FerrariMD, GoadsbyPJ. Ergotamine in the acute treatment of migraine. A review and European consensus. Brain 2000, 123:9–18.
TitusF, LainezJ, LeiraR, DiezE, MonteiroP, DexeusI. Double-blind, multicentric, comparative study of lysin acetylsalicylate (1620 mg equivalent to 900 mg aspirin) + metoclopramide (10 mg) versus ergotamine (2 mg) + caffeine (200 mg) in the treatment of migraine. Cephalalgia 1999, 19:371.
van de VenRC, KajaS, PlompJJ, FrantsRR, Van Den MaagdenbergAM, FerrariMD. Genetic models of migraine. Arch Neurol 2007, 64(5):643–6.
WeillerC, MayA, LimmrothV, JüptnerM, KaubeH, van SchayckR, CoenenHH, DienerHC. Brain stem activation in spontaneous human migraine attacks. Nature Med 1995, 1:658–660.
WelchKMA, MathewMT, StoneP, RosamondW, SaiersJ, GuttermanD. Tolerability of sumatriptan: clinical trials and post-marketing experience. Cephalalgia 2000, 20:687–695.
WessmanM, TerwindtGM, KaunistoMA, PalotieA, OphoffRA. Migraine: a complex genetic disorder. Lancet Neurol 2007, 6(6):521–32.